Secukinumab: Phase 3 Comparative Study for Plaque Psoriasis Completes

A Phase 3 comparative study involving secukinumab (Cosentyx) for patients with moderate to severe plaque psoriasis reached its primary completion on 2025-06-30. The trial, NCT06398652, compared secukinumab against CMAB015 to assess their efficacy, safety, and immunogenicity in this patient population.

Background

Secukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine involved in the pathogenesis of psoriasis. It is approved for various inflammatory conditions, including plaque psoriasis. This trial aimed to compare its profile against another intervention, CMAB015, in the context of moderate to severe chronic plaque psoriasis.

Trial design

The study, identified as NCT06398652, is a Phase 3 comparative trial. It enrolled 336 participants diagnosed with moderate to severe plaque psoriasis. The trial's objective was to assess whether the efficacy of CMAB015 is similar to that of secukinumab, particularly regarding the proportion of patients achieving a 75% improvement in PASI (Psoriasis Area and Severity Index) scores relative to baseline (PASI 75). It also aimed to evaluate the similarity in terms of safety and immunogenicity between CMAB015 and secukinumab.

What this means

The primary completion of this Phase 3 study signifies that all planned data collection for the primary outcome measures has concluded. Researchers will now proceed with data analysis to determine the comparative efficacy, safety, and immunogenicity of CMAB015 versus secukinumab in treating moderate to severe plaque psoriasis. The results, once available, will provide important insights into the potential for CMAB015 as a therapeutic option and its performance relative to an established treatment like secukinumab.

Source

The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06398652, titled 'Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis,' was posted on 2025-06-30 on clinicaltrials.gov.